Safety of tocilizumab in rheumatoid arthritis patients with resolved hepatitis B virus infection: Data from real-world experience

Yonsei Medical Journal

Volumn 59, Issue 3, 2018, Pages 452-456

  Ahn, Sung Soo ^a   Jung, Seung Min ^a   Song, Jason Jungsik ^a   Park, Yong Beom ^a   Park, Jun Yong ^a,b   Lee, Sang Won ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Hepatitis B; Reactivation; Rheumatoid arthritis; Tocilizumab

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; GLUCOCORTICOID; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HYDROXYCHLOROQUINE; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; TACROLIMUS; TOCILIZUMAB; TUMOR NECROSIS FACTOR; ANTIRHEUMATIC AGENT; HEPATITIS B ANTIBODY; MONOCLONAL ANTIBODY; VIRUS DNA;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DAS28; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; TREATMENT DURATION; VIRUS REACTIVATION; BLOOD; GENETICS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MALE; PHYSIOLOGY; RISK FACTOR; TREATMENT OUTCOME; VIROLOGY; VIRUS ACTIVATION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; RISK FACTORS; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 85045026109     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2018.59.3.452     Document Type: Article

References (20)

1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016;388:2023-38.
2. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-19.
3. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-77.
4. Harrold LR, Peterson D, Beard AJ, Gurwitz JH, Briesacher BA. Time trends in medication use and expenditures in older patients with rheumatoid arthritis. Am J Med 2012;125:937.e9-15.
5. Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet 2014; 384:2053-63.
6. Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology 2017;152:1297-309.
7. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009;49(5 Suppl):S156-65.
8. Lee JI. Reactivation of hepatitis B virus in patients with rheumatologic disease treated with biologic disease modifying anti-rheumatic drugs: screening and treatment. J Rheum Dis 2015;22:282-7.
9. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81.
10. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
11. Nakamura J, Nagashima T, Nagatani K, Yoshio T, Iwamoto M, Minota S. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Int J Rheum Dis 2016;19:470-5.
12. Mochida S, Nakao M, Nakayama N, Uchida Y, Nagoshi S, Ido A, et al. Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies. J Gastroenterol 2016;51:999-1010.
13. Kato M, Atsumi T, Kurita T, Odani T, Fujieda Y, Otomo K, et al. Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in Hepatitis B surface antigen-negative cases. J Rheumatol 2011;38:2209-14.
14. Charpin C, Guis S, Colson P, Borentain P, Mattéi JP, Alcaraz P, et al. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther 2009;11:R179.
15. Yang BM, Kim CH, Kim JY. Cost of chronic hepatitis B infection in South Korea. J Clin Gastroenterol 2004;38(10 Suppl 3):S153-7.
16. Kim H, Shin AR, Chung HH, Kim MK, Lee JS, Shim JJ, et al. Recent trends in hepatitis B virus infection in the general Korean population. Korean J Intern Med 2013;28:413-9.
17. Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol 2013;31:118-21.
18. Mori S, Fujiyama S. Hepatitis B virus reactivation associated with antirheumatic therapy: risk and prophylaxis recommendations. World J Gastroenterol 2015;21:10274-89.
19. Lin CT, Huang WN, Hsieh CW, Chen YM, Chen DY, Hsieh TY, et al. Safety and effectiveness of tocilizumab in treating patients with rheumatoid arthritis - A three-year study in Taiwan. J Microbiol Immunol Infect 2017 Jul 1 [Epub]. https://doi.org/10.1016/j.jmii.2017.04.002.
20. Papalopoulos I, Fanouriakis A, Kougkas N, Flouri I, Sourvinos G, Bertsias G, et al. Liver safety of non-tumour necrosis factor inhibitors in rheumatic patients with past hepatitis B virus infection: an observational, controlled, long-term study. Clin Exp Rheumatol 2018;36:102-9.